跳至主要内容
临床试验/NCT01735630
NCT01735630已完成2 期

A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease

OPKO Health, Inc.1 个研究点 分布在 1 个国家目标入组 350 人开始时间: 2012年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
350
试验地点
1
主要终点
Change From Baseline in NPI-C Combined Agitation and Aggression Subscores (NPI-C A+A).

研究概览

简要总结

The primary purpose of this study is to determine whether ELND005 is effective in treating symptoms of agitation and aggression in patients with Alzheimer's disease

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
50 Years 至 95 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of Probable AD according to the National Institute on Aging- Alzheimer's Association (NIA-AA) guidelines (McKhann et al 2011).
  • MMSE score of 5 to 24 (inclusive) at the Screening Visit.
  • Has clinically significant agitation/aggression defined as Neuropsychiatric Inventory (NPI)-agitation/aggression subscore of ≥
  • No response or suboptimal response to standard nonpharmacological interventions.

排除标准

  • The agitation/aggression is attributable to concomitant medications, environmental conditions, or active medical or psychiatric condition.
  • Current diagnosis of major depressive disorder according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition Text Revision (DSM IV TR).
  • Has persistent and distressing psychotic symptoms (delusion and/or hallucinations) that require psychiatric hospitalization.

研究组 & 干预措施

ELND005

Experimental

ELND005 film coated tablets, BID for 12 weeks

干预措施: ELND005 (Drug)

Placebo

Placebo Comparator

Matched placebo BID for 12 weeks

干预措施: Placebo (Drug)

结局指标

主要结局

Change From Baseline in NPI-C Combined Agitation and Aggression Subscores (NPI-C A+A).

时间窗: Week 12

The NPI-C (de Medeiros et al 2010) is a validated and reliable behavioral measure that assesses psychopathology in dementia subjects. It evaluates 14 neuropsychiatric disturbances common in dementia.Higher scores on the NPI-C are associated with a greater clinical severity of symptoms. The NPI-C Agitation and Aggression score ranges from 0-63. The analysis of the NPI-C A+A score was performed on the mITT population.

次要结局

  • Change From Baseline in Modified-ADCS-CGIC Agitation Scores(Week 12)
  • Change From Baseline in NPI Total Scores(Week 12)
  • Change From Baseline in MMSE Scores(Week 12)
  • Change From Baseline in ADCS-ADL Scores(Week 12)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验